Discogenic low back pain

Tanezumab

Tanezumab is a humanised monoclonal immunoglobulin G2 antibody against nerve growth factor that regulates the growth and function of sensory neurons. In randomised controlled trials, tanezumab significantly improved low back pain intensity compared with placebo.[171]Markman JD, Bolash RB, McAlindon TE, et al. Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety. Pain. 2020 Sep 1;161(9):2068-2078. https://www.doi.org/10.1097/j.pain.0000000000001928 http://www.ncbi.nlm.nih.gov/pubmed/32453139?tool=bestpractice.com [172]Kivitz AJ, Gimbel JS, Bramson C, et al. Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain. Pain. 2013 Jul;154(7):1009-21. http://www.ncbi.nlm.nih.gov/pubmed/23628600?tool=bestpractice.com However, advisory committees of the US Food and Drug Administration and the European Medicines Agency have recommended refusing marketing approval for tanezumab, concluding that its benefits in patients (for whom use of non-steroidal anti-inflammatory drugs or opioids is ineffective or inappropriate) did not outweigh its risks. The tanezumab osteoarthritis clinical trial programme has been discontinued.